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• Background 
• Cystic Fibrosis and Treatment 
• Cystic Fibrosis (CF) is a genetic disease, leading to changes of membrane 
secretions causing obstruction of smaller airways 
• CF patients often develop pulmonary infections and require antibiotic 
treatment 
• Loss of lung function increases the risk of death in CF patients  
• Standard treatment involves beta-lactam antibiotics ex. meropenem 
• Pharmacokinetics and Pharmacodynamics of Meropenem 
• Meropenem is a broad spectrum beta lactam that acts by lysing microbes 
through interfering with bacterial cell wall synthesis.  
• Safe and effective treatment, however data on pediatric patients is limited 
• Effectiveness of meropenem determined by time sensitive dosing and is 
effective only when the minimum inhibitory concentration (MIC) is reached 
• Meropenem can be administered as a continuous infusion or intermittent 
bolus 
• Significance of the Problem 
• There is a lack of information regarding the use of meropenem in pediatric CF 
patients 
• There is a lack of supporting information for the use of one treatment regimen 
over the other 
• Quality of Life – CF patients struggle with malnutrition and treatment with 
meropenem compounds the problem due to significant nausea  
• Would a different dosing regimen reduce side effects of meropenem treatment? 
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STATEMENT OF THE PROBLEM 
To test establish clinical protocols for meropenem administration in pediatric CF 
patients admitted to Dayton Children’s with the goal of reducing nausea as a side 
effect.  
To assess reported nausea and its relationship to serum concentration of 
meropenem in pediatric CF patients after administration of meropenem in either a 
continuous or intermittent IV infusion.  
OBJECTIVES 
PROPOSED METHODS 
Study Design 
Crossover study designed to compare blood levels of meropenem and effect on 
nausea in pediatric cystic fibrosis patients 
Sample 
This pilot study will comprise approximately 10 subjects from ages seven to 
twenty-one 
Data Collection and Measurement 
Cross over study 
• Patients randomly divided into two treatment groups 
• One initially receives intermittent dosing of meropenem  
• One receives continuous infusion of meropenem 
• Then groups will switch after four days 
• Continuous dose 120 mg/kg/day  
• Intermittent dose 40 mg/kg/dose infused over 30 minutes every 8 hours 
Serum Meropenem 
• Determined through blood draw  
• Intermittent dose: After the third dose 
• Continuous dose: After day three  
Nausea Scale 
• Levels of nausea will be determined by recording frequency of Kytril doses 
requested 
PICC line 
• Sub-study to be conducted to determine reliability of serum levels taken from 
PICC line 
• Serum levels of meropenem in both groups compared between PICC line 
blood draws and peripheral blood draws. 
HPLC Assay 
• Meropenem concentrations will be measured utilizing a High Pressure Liquid 
Chromatography (HPLC) instrument 
 
 
 
 
 
 HYPOTHESES 
Null Hypotheses:  
•Continuous IV administration of 
meropenem will have no effect on the 
side effects of nausea when compared to 
intermittent administration. 
 
•The differences in serum concentrations 
between intermittent and continuous IV 
administration of meropenem do not 
change the number of dosages of anti-
nausea medications ordered in pediatric 
CF patients 
 
 
• Small sample size will limit the generalizability of the results. 
• Additional medication regimens may contribute to nausea. 
LIMITATIONS 
The goal of this study is to provide a 
framework for further multi-site studies of 
the same nature.  
FUTURE DIRECTION 
Alternative hypotheses: 
•Continuous IV administration of 
meropenem will reduce the side effects 
of nausea when compared to 
intermittent administration 
 
•The differences in serum concentration 
between intermittent and continuous IV 
administration of meropenem do change 
the number of dosages of anti-nausea 
medications ordered in pediatric CF 
patients  
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Nausea levels: average the doses of Kytril requested by each patient, number of 
episodes of emesis 
Two tailed t test (α =0.05, and β = 0.2) 
Comparison of the means of two treatment arms. 
Concentration of meropenem in blood 
Arithmetic mean will be calculated for each sample (95% confidence interval) 
Comparison of Treatment Arms 
Two-tailed t-test will be used to compare means of the two treatment arms 
Two-tailed t-test will be used to compare the two types of blood draw methods 
PROPOSED ANALAYSES 
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